Physician profile
Marshall B Sack
NPI 1629071170
$5,688.15
in general payments reported to CMS, 2019-2025
44 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $481 · 2021: $894 · 2022: $827 · 2023: $672 · 2024: $880 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,995.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $948.58 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $556.28 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $501.45 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $325.80 | 2020-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $272.93 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $257.30 | 2019-2025 | Rexulti |
| Pfizer INC. | $244.90 | 2020-2025 | |
| Novo Nordisk INC | $212.26 | 2023-2025 | Wegovy |
| Glaxosmithkline, LLC. | $202.39 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $169.39 | 2019-2024 | Trintellix |
| Medline Industries LP | $164.55 | 2019 | |
| Allergan, INC. | $147.10 | 2019-2020 | |
| Astellas Pharma US INC | $138.21 | 2019-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $133.67 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $119.32 | 2020 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $118.58 | 2021-2025 | Repatha, Otezla, Repatha |
| Esperion Therapeutics, INC. | $95.22 | 2021-2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $86.72 | 2022-2025 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $79.20 | 2020-2025 | Spravato |
| Tris Pharma INC | $78.53 | 2019-2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $78.34 | 2019-2023 | Jornay Pm |
| Bausch Health US, LLC | $72.50 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $65.94 | 2025 | Fanapt |
| Sumitomo Pharma America, INC. | $65.51 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $63.66 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $59.62 | 2024-2025 | Cobenfy |
| Lilly USA, LLC | $56.08 | 2019-2025 | Zepbound, Jardiance |
| Adlon Therapeutics L.P. | $50.79 | 2020-2021 | |
| Sanofi Pasteur INC. | $41.88 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $34.00 | 2023 | |
| Abbott Laboratories | $24.24 | 2025 | Freestyle Libre 3 |
| Alkermes, INC. | $22.08 | 2023 | Aristada, Lybalvi |
| Optinose US, INC. | $21.44 | 2021 | |
| Corium, LLC | $20.24 | 2022 | |
| Validus Pharmaceuticals LLC | $20.00 | 2025 | Lopressor |
| Axsome Therapeutics, INC. | $18.98 | 2025 | Auvelity |
| Noven Therapeutics, LLC | $17.64 | 2024 | Xelstrym |
| Biohaven Pharmaceutical Holding Company LTD. | $16.47 | 2022 | |
| Inari Medical, INC. | $16.43 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Impel Pharmaceuticals INC. | $15.50 | 2022 | |
| Kaleo, INC. | $15.07 | 2021 | |
| Alfasigma USA, INC. | $13.47 | 2022 | |
| Almatica Pharma LLC | $13.19 | 2022 | |
| Biogen, INC. | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Sack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.